NCT05710328 2026-03-02
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
Clinical Trials
12 trialsNCT02926911 2026-01-27
COMET
Alliance Foundation Trials, LLC.
Phase NA Active not recruiting
NCT05278741 2025-12-26
BREAST
Centre Georges Francois Leclerc
Phase NA Active not recruiting
NCT00929214 2025-12-17
Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01723774 2025-12-09
PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
Washington University School of Medicine
Phase 2 Active not recruiting
NCT06027541 2025-08-03
Young Patients With Early Breast Cancer
Peking Union Medical College Hospital
Active not recruiting
NCT03725059 2025-07-11
KEYNOTE-756
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04997941 2024-04-23
MORE-T
Seoul National University Hospital
Phase 2 Active not recruiting
NCT03595592 2024-03-06
APTneo
Fondazione Michelangelo
Phase 3 Active not recruiting
NCT01717131 2024-01-11
Axillary Node Dissection Versus no Dissection in Breast Cancer With Positive Sentinel Lymph Node
Institut Paoli-Calmettes
Phase NA Active not recruiting
NCT02400658 2023-01-25
Efficacy of IORT With CT-Guided HDR Brachytherapy for Treatment of Breast Cancer
University of Virginia
Phase NA Active not recruiting
NCT04398914 2022-03-31
Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
Shanghai Jiao Tong University School of Medicine
Phase 2 Active not recruiting